A genus patent covers the species of its subsequent applications, non-working cannot bear on the patentee's rights under section 48, and the defendants were restrained till trial.
Summary
“The plaintiffs have instituted this suit for permanent injunction for restraining the defendants from manufacturing, selling, distributing, exporting or offering for sale of any product that infringes the plaintiffs’ patent No. 215528 including Lorcaserin or any of its pharmaceutically acceptable salts including Lorcaserin Hydrochloride (hereinafter referred to as ‘LH’) and Lorcaserin Hydrochloride Hemihydrate (hereinafter referred to as ‘LHH’)” and “In I.A. 13934/2018, the plaintiffs are seeking interim injunction against the defendants.” (para 1) “The plaintiff applied for patent in India on 23rd September, 2004 in pursuance to which patent No.215528 was granted on 27th February, 2008 for the period of 20 years i.e. from 11th April, 2003 till 10th April, 2023.” (para 6) “In late August, 2018, the plaintiffs found that the defendants were planning to commercialize Lorcaserin in Indian market” and “The plaintiffs promptly filed the present lawsuit on 5th October, 2018.” (para 8) “The defendants appeared before this Court on the very first date i.e. 08th October, 2018 to oppose the injunction” (para 2), and the Court “examined the officers of the defendants on oath in exercise of the power under Section 165 of the Indian Evidence Act.” (para 49)
The Court held that “The plaintiffs have made out a strong prima facie case for grant of interim injunction against the defendants” (para 50), that “The plaintiffs’ patent No.215528 covers Lorcaserin and its pharmaceutically acceptable salts, including LHH” (para 50.5), and that “this Court is satisfied with the plaintiffs’ explanation that the suit patent is in the nature of an originating/genus patent and the various subsequent patent applications are for improvement/ selection inventions” (para 50.9). On the rival admissions it held that “The plaintiffs have satisfactorily explained the aforesaid admissions referred to by the defendants whereas this Court is not satisfied with the explanation of the defendants to their admissions” (para 50.10), and on non-working that “The non-working of a patent particularly for a pharmaceutical product cannot have a bearing on the rights of a patentee under Section 48 of the Patents Act, 1970.” (para 50.11) “The balance of convenience for the grant of interim injunction lies in favour of the plaintiffs as the defendants have evidently not ‘cleared the way’ before going ahead with obtaining a marketing approval for launch of the infringing drug.” (para 51) “In the facts and circumstances of this case, the application is allowed and the defendants are restrained from making, using, selling, distributing, advertising, exporting, offering for sale, and in any other manner, directly or indirectly dealing in any product that infringes the claimed subject matter of the Plaintiffs’ Indian Patent No.215528 or any of the claims thereof including Lorcaserin or Lorcaserin Hydrochloride, LHH and any forms thereof till the disposal of the suit.” (para 54)
What the court decided
- Procedure. Examination of the defendants’ officers. “During the course of hearing dated 21st December, 2018 and 14th January, 2019, this Court examined the officers of the defendants on oath in exercise of the power under Section 165 of the Indian Evidence Act. The statements of the officers recorded by this Court are relevant and are reproduced herein below” (para 49)
- The suit patent undisturbed. “Plaintiff No.2 applied for patent in India on 23rd September, 2004 in pursuance to which patent No.215528 was granted on 27th February, 2008 for the period of 20 years from 11th April, 2003 till 10th April, 2023. There were no pre-grant oppositions and no post-grant oppositions. The suit patent has existed undisturbed on the register for more than 10 years.” (para 50.3)
- Coverage of the salts. “The plaintiffs’ patent No.215528 covers Lorcaserin and its pharmaceutically acceptable salts, including LHH” (“Lorcaserin Hydrochloride Hemihydrate”) and “Claims 38 and 39 specifically claim Lorcaserin and all its pharmaceutically acceptable salts and hydrates.” (para 50.5)
- The defendants’ admissions. “The defendants have admitted in the statement dated 14th January, 2019 of Mr. Girish Parhate, Director (Regulatory Affairs) of the defendant that their drug is covered by the plaintiffs’ patent”, that “The defendants, in their US patent application 2014/0187538A1 admitted that the PCT application corresponding to the suit patent i.e. WO2003/086306 discloses Lorcaserin” and that “In the pre-grant opposition filed by the defendants against the plaintiffs’ pending Indian Patent Application No. 311/KOLNP/2009 for LHH, the defendants admitted that in PCT application WO2003/086306, (suit patent) there is explicit and unambiguous disclosure of hydrochloride salt of Lorcaserin and method of preparing thereof.” (paras 50.6–50.8)
- The genus and the species. “this Court is satisfied with the plaintiffs’ explanation that the suit patent is in the nature of an originating/genus patent and the various subsequent patent applications are for improvement/ selection inventions, which specifically disclose and claim a particular ‘species’ of the genus patent, i.e. the hydrochloride hemihydrate form. Merely because the plaintiffs have applied for a patent separately for a specific species of the genus, it does not mean that the species patent cannot be granted or that the species patent would not fall within the coverage of the genus patent (i.e. the suit patent in the present case). Grant of a subsequent patent, which is an improvement invention, does not take the said forms out of the first/basic patent, which in the present case is the suit patent.” (para 50.9)
- The rival admissions. “The plaintiffs have strongly relied upon the admissions of the defendants in the statement made before this Court on 22nd December, 2018 & 14th January, 2019 and the US patent application referred in para 11 above whereas the defendants have strongly relied upon the plaintiffs’ admission made in the reply dated 15th January, 2018 and 16th April, 2018. The plaintiffs have satisfactorily explained the aforesaid admissions referred to by the defendants whereas this Court is not satisfied with the explanation of the defendants to their admissions. The admissions of the defendants are sufficient to grant the injunction against the defendants.” (para 50.10)
- Non-working and section 48. “With respect to the defendants’ contention that the plaintiffs have not worked out the suit patent in India; the defendants had a remedy to seek a compulsory License under Sections 83 and 84 of the Patents Act, 1970. However, the defendants, instead of applying for either a voluntary license or a compulsory license, decided to go ahead on their own volition and seek a marketing approval. The non-working of a patent particularly for a pharmaceutical product cannot have a bearing on the rights of a patentee under Section 48 of the Patents Act, 1970.” Reference was made to Cipla v Novartis (2017). (para 50.11)
- Franz Xaver Huemer distinguished. Of Franz Xaver Huemer v New Yash Engineers (1996), the Court held that it “related to a special kind of loom which was vital for the textile industry of the country and which would affect the economy of the country, thereby seriously affecting the market and economy” and that “In that case, the defendants’ products were already out in the market. Moreover, this case is prior to 2005 and there have been significant changes in the compulsory licensing regime under Sections 83 and 84 of the Patents Act, as a result of the amendment to the Patents Act in 2005.” (para 50.12)
- Validity and the recording of evidence. “The defendants’ objections to the validity of the suit patent under Section 3(d) as well as Section 64(1)(d), 64(1)(e), 64(1)(f), 64(1)(j), 64(1)(k), 64(1) (o) read with Section 2(1)(j), 3(e) and 3(i) of the Patents Act cannot be decided without recording of evidence.” (para 50.13)
- Clearing the way. “The balance of convenience for the grant of interim injunction lies in favour of the plaintiffs as the defendants have evidently not ‘cleared the way’ before going ahead with obtaining a marketing approval for launch of the infringing drug. The defendants were aware that there may be a possible challenge to its product, but they chose to go ahead to seek the marketing approvals without first invoking revocation proceedings or attempting to obtain a licensee. Where litigation is bound to ensue if the defendants introduce their product, the defendants could have avoided the interlocutory injunction if they had cleared the way first.” Reference was made to Merck Sharp and Dohme v Glenmark Pharmaceuticals (2015). (para 51)
- Irreparable injury. “The plaintiffs shall suffer irreparably if the injunction is not granted. On the other hand, the defendants obtained manufacturing approval on 22nd October, 2018 and have not commenced the manufacturing of the infringing product. If the defendants are permitted to market its product pending trial, the loss to the plaintiffs cannot be compensated in terms of the money.” (para 52)
- A prima facie view. “The Court, at the interim stage, has to take a prima facie view of the matter. In that view of the matter, the dissection and analysis of all the submissions is not warranted at this stage.” (para 53)
- Disposition. “In the facts and circumstances of this case, the application is allowed and the defendants are restrained from making, using, selling, distributing, advertising, exporting, offering for sale, and in any other manner, directly or indirectly dealing in any product that infringes the claimed subject matter of the Plaintiffs’ Indian Patent No.215528 or any of the claims thereof including Lorcaserin or Lorcaserin Hydrochloride, LHH and any forms thereof till the disposal of the suit.” (para 54)
- Procedure. Costs and cost estimates. “The plaintiffs are entitled to the costs from the defendants. However, the order as to quantum of costs is deferred till the final decision of this suit. Both the parties are directed to submit the actual cost incurred by them. The parties are also directed to submit their estimate of future cost before the commencement of trial so that the parties shall have notice of actual cost that the other side estimate would be incurring in the course of litigation and the parties have an opportunity to take appropriate decision as to manner in which to conduct the litigation. Greater transparency about cost will promote access to justice.” (para 55)
What the court did not decide
“The observations made hereinabove are prima facie for the purpose of deciding this application and shall not constitute any expression of final opinion on the merits of this case.” (para 56)
Subsequent treatment
- Followed — In Nocil v Finorchem (2026) the Calcutta High Court held that a defendant must “clear the way i.e. remove all obstacles before commencing its activities rather than waiting to be sued for infringement”, and that a failure to “clear the path” “is also a factor which would weigh with the Court at this prima facie stage”, citing this case among its authorities (para 15).
- No further appeal traced as of 28 October 2026.